This site is intended for healthcare professionals only
Share this article

UK Kidney Association releases guideline on SGLT2 inhibitor use

The UK Kidney Association has released its Clinical Practice Guideline on sodium–glucose cotransporter 2 (SGLT2) inhibitor use in adults with kidney disease. Studies have demonstrated that these agents have particular efficacy at reducing  risk of kidney disease progression in people with type 2 diabetes and albuminuric diabetic kidney disease, and that these benefits may extend to certain types of albuminuric renal disease irrespective of the presence of diabetes.

Therefore, the aim of the guidelines is to facilitate rapid and safe use of SGLT2 inhibitors in the context of chronic kidney disease, focusing on the  potential to modify risk of kidney disease progression, and to support the safe implementation of SGLT2 inhibitors in clinical practice.

Click here to read the guideline.

Related content
Free for all UK & Ireland healthcare professionals

Sign up to all DiabetesontheNet journals


By clicking ‘Subscribe’, you are agreeing that are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.

We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.